{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:14:38Z","timestamp":1783440878737,"version":"3.54.6"},"reference-count":61,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Monomorphic posttransplant lymphoproliferative disorders (PTLDs) beyond diffuse large B-cell lymphoma (DLBCL) are rare, biologically heterogeneous entities with limited prospective data to guide treatment. DLBCL-PTLD, which comprises most cases, is managed using approaches informed by prospective phase 2 studies, including reduction in immunosuppression and a risk-adapted sequential immunochemotherapy approach. In contrast, non-DLBCL subtypes such as Burkitt lymphoma, PTLDs of T\/NK-cell origin, and plasmacytic variants are less common and are typically treated using strategies extrapolated from established treatment algorithms used in immunocompetent patients and sporadic case reports. Classic Hodgkin lymphoma PTLD, although not classified as monomorphic, represents another distinct and clinically relevant subtype. This review summarizes the epidemiology, clinical features, treatment strategies, and outcomes associated with these less common PTLDs, aiming to provide a practical framework for their management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016930","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T20:59:03Z","timestamp":1755205143000},"page":"5792-5801","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"3","key":"2025112509012758100_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2025112509012758100_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2025112509012758100_bib3","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1097\/HS9.0000000000000640","article-title":"Clinicopathologic characteristics, treatment, and outcomes of post-transplant lymphoproliferative disorders: a single-institution experience using 2017 WHO Diagnostic Criteria","volume":"5","author":"King","year":"2021","journal-title":"Hemasphere"},{"issue":"8","key":"2025112509012758100_bib4","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2352-3026(20)30126-5","article-title":"HIV-associated Burkitt lymphoma","volume":"7","author":"Atallah-Yunes","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5 Pt 1","key":"2025112509012758100_bib5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1600-6143.2006.01294.x","article-title":"Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival","volume":"6","author":"Kremers","year":"2006","journal-title":"Am J Transpl"},{"issue":"2","key":"2025112509012758100_bib6","first-page":"214","article-title":"Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations","volume":"14","author":"Walker","year":"1995","journal-title":"J Heart Lung Transpl"},{"issue":"2","key":"2025112509012758100_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025112509012758100_bib8","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41375-022-01667-1","article-title":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell post-transplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial","volume":"36","author":"Zimmermann","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2025112509012758100_bib9","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00277-018-3473-8","article-title":"Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series","volume":"97","author":"Bobillo","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"2025112509012758100_bib10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/ajt.12211","article-title":"Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era","volume":"13","author":"Evens","year":"2013","journal-title":"Am J Transpl"},{"issue":"13","key":"2025112509012758100_bib11","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/bloodadvances.2022009521","article-title":"Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS","volume":"7","author":"Guney","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2025112509012758100_bib12","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3109\/10428194.2013.775436","article-title":"Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases","volume":"54","author":"Herreman","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025112509012758100_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2020.267294","article-title":"Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas","volume":"107","author":"Leeman-Neill","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"2025112509012758100_bib14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/ajh.25988","article-title":"The clinical and pathological features of plasma cell myeloma post solid organ transplantation","volume":"95","author":"Ofori","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"2025112509012758100_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1309\/AJCPX70TIHETNBRL","article-title":"Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features","volume":"132","author":"Richendollar","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2025112509012758100_bib16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1309\/LYXN3RGF7D7KPYG0","article-title":"T-cell and NK-cell posttransplantation lymphoproliferative disorders","volume":"127","author":"Swerdlow","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"2025112509012758100_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2010.039214","article-title":"Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases","volume":"96","author":"Trappe","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"2025112509012758100_bib18","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.3324\/haematol.2022.282297","article-title":"Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients","volume":"108","author":"Walczak","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"2025112509012758100_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/TP.0b013e318242162d","article-title":"Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry","volume":"93","author":"Zimmermann","year":"2012","journal-title":"Transplantation"},{"issue":"19","key":"2025112509012758100_bib20","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.27482","article-title":"Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients","volume":"118","author":"Zimmermann","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"2025112509012758100_bib21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.tp.0000203554.54242.56","article-title":"Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis","volume":"81","author":"Caillard","year":"2006","journal-title":"Transplantation"},{"issue":"6","key":"2025112509012758100_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.24346","article-title":"Hodgkin lymphoma post-transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival","volume":"91","author":"Rosenberg","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2025112509012758100_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.23385","article-title":"Burkitt lymphoma risk in U.S. solid organ transplant recipients","volume":"88","author":"Mbulaiteye","year":"2013","journal-title":"Am J Hematol"},{"issue":"1408","key":"2025112509012758100_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1098\/rstb.2000.0783","article-title":"Biology and disease associations of Epstein-Barr virus","volume":"356","author":"Crawford","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"2025112509012758100_bib25","first-page":"150835","article-title":"Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?","volume":"2013","author":"Morscio","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"7","key":"2025112509012758100_bib26","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.3324\/haematol.2015.124305","article-title":"Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain\/loss pattern","volume":"100","author":"Ferreiro","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2025112509012758100_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.16425","article-title":"Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients","volume":"189","author":"Jakobsen","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2025112509012758100_bib28","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"2025112509012758100_bib29","doi-asserted-by":"crossref","first-page":"963689721996649","DOI":"10.1177\/0963689721996649","article-title":"Successful treatment of pediatric refractory Burkitt lymphoma PTLD after liver transplantation using anti-CD19 chimeric antigen receptor T-cell therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Cell Transpl"},{"issue":"6","key":"2025112509012758100_bib30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1125>3.0.CO;2-N","article-title":"Lymphoproliferative disorders in renal transplant patients in Japan","volume":"91","author":"Hoshida","year":"2001","journal-title":"Int J Cancer"},{"issue":"23","key":"2025112509012758100_bib31","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.3390\/cancers14235949","article-title":"Recent advances in adult post-transplant lymphoproliferative disorder","volume":"14","author":"Markouli","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2025112509012758100_bib32","doi-asserted-by":"crossref","first-page":"100039","DOI":"10.1016\/j.bneo.2024.100039","article-title":"Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation","volume":"1","author":"Cheng","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"7","key":"2025112509012758100_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"2025112509012758100_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4049\/jimmunol.146.3.865","article-title":"Expression of CR2 (the C3dg\/EBV receptor, CD21) on normal human peripheral blood T lymphocytes","volume":"146","author":"Fischer","year":"1991","journal-title":"J Immunol"},{"issue":"3","key":"2025112509012758100_bib35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/pbc.20231","article-title":"Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature","volume":"44","author":"George","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"2025112509012758100_bib36","doi-asserted-by":"crossref","first-page":"37636","DOI":"10.18632\/oncotarget.9400","article-title":"Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders","volume":"7","author":"Margolskee","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"2025112509012758100_bib37","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/TP.0000000000001099","article-title":"T cell PTLD successfully treated with single-agent brentuximab vedotin first-line therapy","volume":"100","author":"Choi","year":"2016","journal-title":"Transplantation"},{"issue":"9","key":"2025112509012758100_bib38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/lt.23918","article-title":"First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis","volume":"20","author":"Schaefer","year":"2014","journal-title":"Liver Transpl"},{"issue":"11","key":"2025112509012758100_bib39","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transpl"},{"issue":"6","key":"2025112509012758100_bib40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/tri.12091","article-title":"Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients","volume":"26","author":"Karuturi","year":"2013","journal-title":"Transpl Int"},{"issue":"6","key":"2025112509012758100_bib41","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/ajt.12234","article-title":"Plasma cell neoplasms in US solid organ transplant recipients","volume":"13","author":"Engels","year":"2013","journal-title":"Am J Transpl"},{"issue":"1","key":"2025112509012758100_bib42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ctr.12482","article-title":"Multiple myeloma after kidney transplantation","volume":"29","author":"Safadi","year":"2015","journal-title":"Clin Transpl"},{"issue":"8","key":"2025112509012758100_bib43","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ajh.27376","article-title":"Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Ramirez-Gamero","year":"2024","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025112509012758100_bib44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood-2024-211388","article-title":"Daratumumab with dose-adjusted EPOCH is feasible in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105","volume":"144","author":"Noy","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025112509012758100_bib45","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.transproceed.2004.12.130","article-title":"Posttransplant lymphoproliferative disorder: significance of central nervous system involvement","volume":"37","author":"Buell","year":"2005","journal-title":"Transpl Proc"},{"issue":"4","key":"2025112509012758100_bib46","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.24834","article-title":"Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report","volume":"116","author":"Cavaliere","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"2025112509012758100_bib47","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.radcr.2024.02.030","article-title":"Primary central nervous system post-transplantation lymphoproliferative disorder: a case report and systematic review of imaging findings","volume":"19","author":"Hoyt","year":"2024","journal-title":"Radiol Case Rep"},{"issue":"1","key":"2025112509012758100_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13244-019-0726-6","article-title":"Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential","volume":"10","author":"White","year":"2019","journal-title":"Insights Imaging"},{"issue":"31","key":"2025112509012758100_bib49","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","article-title":"CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation","volume":"25","author":"Maecker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025112509012758100_bib50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/bloodadvances.2024014073","article-title":"Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience","volume":"9","author":"Hwang","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"2025112509012758100_bib51","doi-asserted-by":"crossref","first-page":"LBA-3","DOI":"10.1182\/blood-2022-171733","article-title":"Effects on survival of non-myeloablative chemoimmunotherapy compared to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as consolidation therapy in patients with primary CNS lymphoma-results of an international randomized phase III trial (MATRix\/IELSG43)","volume":"140","author":"Illerhaus","year":"2022","journal-title":"Blood"},{"key":"2025112509012758100_bib52","doi-asserted-by":"crossref","first-page":"1284577","DOI":"10.3389\/fonc.2024.1284577","article-title":"Primary central nervous system post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation: a case report","volume":"14","author":"Tugend","year":"2024","journal-title":"Front Oncol"},{"issue":"2","key":"2025112509012758100_bib53","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1016\/j.jtct.2025.01.806","article-title":"Updated clinical results: a multicenter, open-label, phase 3 study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein\u2013Barr virus\u2013driven posttransplant lymphoproliferative disease after failure of rituximab or rituximab plus chemotherapy","volume":"31","author":"Ghobadi","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2025112509012758100_bib54","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1016\/j.jtct.2023.12.495","article-title":"Clinical experience of tabelecleucel in Epstein\u2013Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) involving the central nervous system","volume":"30","author":"Baiocchi","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"2025112509012758100_bib55","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"2025112509012758100_bib56","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2025112509012758100_bib57","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab + AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2025112509012758100_bib58","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"issue":"9","key":"2025112509012758100_bib59","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + Tacrolimus + Prednisone \u00b1 Ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025112509012758100_bib60","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00277-023-05446-5","article-title":"Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review","volume":"103","author":"Zhou","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"2025112509012758100_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clml.2021.09.018","article-title":"Brentuximab vedotin and bendamustine produce long-term clinical benefit in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter real-life experience","volume":"22","author":"Moretti","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5792\/2420414\/blooda_adv-2025-016930-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5792\/2420414\/blooda_adv-2025-016930-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:01:37Z","timestamp":1764079297000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5792\/546728\/Non-DLBCL-monomorphic-and-Hodgkin-lymphoma-PTLD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":61,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016930","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,14]]}}}